NewLink Genetics (NLNK +14%) is up on modestly higher volume in early trade. Two days ago, development partner Merck (MRK -1.2%) started the rolling submission of its U.S. marketing application seeking approval for Ebola vaccine V920.
This morning, NLNK announced that Merck will receive a Priority Review Voucher upon FDA approval which can be used for accelerated review of a future application or it can be sold to a third party. NLNK says it has a "substantial economic interest" in the voucher and has the right to monetized its share.
Previously: Merck starts rolling BLA for Ebola vaccine (Nov. 13)
Subscribe for full text news in your inbox